Drug profile · INN
agalsidase alfa
REPLAGAL
agalsidase alfa (REPLAGAL) is a globotriosylceramide hydrolytic enzyme. Associated with Takeda.
EMA: approved Alimentary tract and metabolism (A16) A16AB03
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — agalsidase alfa
- Class
- Alimentary tract and metabolism (A16)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.89
Quick answer
agalsidase alfa (REPLAGAL) is a globotriosylceramide hydrolytic enzyme. Associated with Takeda.
Key facts
INN agalsidase alfa
Brand REPLAGAL
Mechanism Globotriosylceramide hydrolytic enzyme
Target Globotriosylceramide
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AB03
Originator Takeda
Mechanism of action
Globotriosylceramide hydrolytic enzyme
Primary target: Globotriosylceramide
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is agalsidase alfa?
agalsidase alfa (REPLAGAL) is a globotriosylceramide hydrolytic enzyme. Associated with Takeda.
What is the brand name for agalsidase alfa?
REPLAGAL is a marketed brand name for agalsidase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.